Related Experiment Video
Updated: Jun 28, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
Targeting Cav2.2 channels for pain management: challenges, innovations, and future perspectives
Fangla Luo1, Junwei Su1, Xinlong Ke1
1Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China.
None:
N-type voltage-gated calcium channels (Cav2.2) are validated targets for chronic pain management. Although ziconotide is clinically effective, its use is hampered by a narrow therapeutic window and severe side effects. This review examines the subunit structure of Cav2.2 and its fundamental role in nociceptive signaling. We focus on emerging therapeutic strategies developed in recent years, including the optimization of direct blockade, the inhibition of channel trafficking, the modulation of signaling pathways, and targeted channel depletion. These advancements provide a deeper understanding of calcium channel regulation and identify promising targets for safer, more effective, and precision-based pain management.
Related Concept Videos
Analgesia and Pain Management
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Modified-Release Drug Delivery Systems: Site-Targeted
